107 related articles for article (PubMed ID: 10664245)
1. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
Voelcker G; Pfeiffer B; Schnee A; Hohorst H
J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
[TBL] [Abstract][Full Text] [Related]
2. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
Voelcker G
Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
Voelcker G
Anticancer Drugs; 2018 Jun; 29(5):411-415. PubMed ID: 29465464
[TBL] [Abstract][Full Text] [Related]
4. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester.
Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1998; 124(6):297-300. PubMed ID: 9692835
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 1-aldofosfamide-perhydrothiazines.
Zimmermann J; Bauer HH; Hohorst HJ; Voelcker G
Arzneimittelforschung; 2000 Sep; 50(9):843-7. PubMed ID: 11050703
[TBL] [Abstract][Full Text] [Related]
6. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
7. Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters.
Karapidaki I; Bakopoulou A; Papageorgiou A; Iakovidou Z; Mioglou E; Nikolaropoulos S; Mourelatos D; Lialiaris T
Mutat Res; 2009 Apr; 675(1-2):51-9. PubMed ID: 19386248
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
[TBL] [Abstract][Full Text] [Related]
9. Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Misiura K; Szymanowicz D; Kuśnierczyk H; Wietrzyk J; Opolski A
Acta Biochim Pol; 2002; 49(1):169-76. PubMed ID: 12136937
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
Voelcker G; Bielicki L; Hohorst HJ
J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
Hładoń B; Sloderbach A; Laskowska H
Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferation effects of hexadecylphosphocholine on solid tumour and leukaemia selectively in vitro.
Wang YZ; Liu XY; Wu LJ; Zhang YB; Hou L; Xu QS
Drugs Exp Clin Res; 1997; 23(3-4):97-102. PubMed ID: 9403269
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumour activity of several new 4-aroyl-1-nitrosohydrazinecarboxamides.
Gugova R; Topakbashian V; Lozeva S; Dimov S; Golovinsky E
Drugs Exp Clin Res; 1997; 23(2):71-5. PubMed ID: 9309382
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.
Voelcker G
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1183-9. PubMed ID: 26941190
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):285-91. PubMed ID: 3592932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
